Results 91 to 100 of about 36,124 (280)

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

International Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, Delphine Argo Leignel, Philippe Ronchin, Ariane Darut Jouve, Véronique Vendrely, Olivier Riou, Jérôme Martin‐Babau, Thomas Leroy, Laurent Quéro, Naïma Hanoun, Pierre Cordelier, Veronica Pezzella, Jean Pierre Delord, Rosine Guimbaud, Elizabeth Moyal, Catherine Seva   +21 more
wiley   +1 more source

Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels

Blood Advances
Abstract Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool in 77 DLBCL cases with both ctDNA and tissue biopsy, a 95.8% concordance rate in molecular cluster assignment
Riccardo Moia, Donatella Talotta, Lodovico Terzi Di Bergamo, Mohammad Almasri, Riccardo Dondolin, Matin Salehi, Chiara Cosentino, Roberta Soscia, Irene Della Starza, Alessio Bruscaggin, Annalisa Andorno, Francesca Mercalli, Stefania Cresta, Riccardo Bomben, Tamara Bittolo, Filippo Vit, Pietro Bulian, Antonella Zucchetto, Riccardo Bruna, Giulia Maria Rivolta, Mattia Schipani, Eleonora Secomandi, Sreekar Kogila, Matteo Bellia, Samir Mouhssine, Jana Nabki, Bashar Al Deeban, Joseph Ghanej, Luca Cividini, Nawar Maher, Federica Melle, Giovanna Motta, Monica Leutner, Angela Lorenzi, Abdurraouf Mokhtar Mahmoud, Wael Al Essa, Clara Deambrogi, Silvia Rasi, Luigi Petrucci, Renzo Luciano Boldorini, Alice Di Rocco, Ilaria Del Giudice, Michele Spina, Stefano Palazzolo, Fabio Canal, Vincenzo Canzonieri, Maurizio Martelli, Stefano Pileri, Valter Gattei, Robin Foà, Davide Rossi, Gianluca Gaidano   +51 more
openaire   +6 more sources

La integración de la prueba de ctDNA en el análisis de EGFR en el carcinoma pulmonar no microcítico: estrategias para el laboratorio clínico

Advances in Laboratory Medicine
El análisis molecular del gen receptor del factor de crecimiento epidérmico (EGFR) resulta fundamental a la hora de seleccionar una terapia dirigida para el carcinoma pulmonar no microcítico avanzado (CPNM).
Fernández-Galán Esther, Puig-Butillé Joan Anton   +1 more
doaj   +1 more source

Tumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation

International Journal of Cancer, EarlyView.
Abstract Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome ...
Whi‐An Kwon, Min‐Kyung Lee, Eunyong Ahn, Heeyeon Kim, Yong Sang Song, Taejin Ahn   +5 more
wiley   +1 more source

Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs [PDF]

, 2017
Circulating nucleic acids (CNAs), for example, circulating tumor DNA (ctDNA) and circulating microRNA (miRNA), represent promising biomarkers in several diseases including cancer.
A Hruštincová, A Sonnenberg, A Sonnenberg, AM Newman, AS Devonshire, C Bettegowda, C Blenkiron, C Fang, C Steudemann, CJ Creighton, D Hashad, DW Swinkels, EM Kroh, FC Bidard, HH Cheng, JA Weber, KC Chan, KL Spindler, KL Spindler, L Sorber, L Sorber, M Filková, M Monleau, M Xiang, MB Kirschner, MP Hunter, N Karachaliou, N Umetani, PO Delgado, RW Chiu, U Malapelle, V Taly, X Chen, Z Wang   +33 more
core   +1 more source

Blood‐Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations

International Journal of Cancer, EarlyView.
Early detection of colorectal cancer via population‐based screening programs can reduce incidence and mortality, but current screening approaches are limited. This systematic review evaluated the screening potential of blood‐based circulating tumor DNA assays in asymptomatic screening populations.
Caroline Ledertoug Kahn, Maria Wissing Rasmussen, Jakob Kleif, Inge Søkilde Pedersen, Christina Therkildsen   +4 more
wiley   +1 more source

Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma

International Journal of Cancer, EarlyView.
Commercial circulating tumor DNA (ctDNA) liquid biopsy tests are increasingly used for disease monitoring and surveillance in melanoma. However, data regarding the possible correlations between ctDNA and baseline clinical and radiometabolic parameters such as metastatic locations, tumor volume, and tumor glycolysis in patients with BRAF‐mutated ...
Ronen Stoff, Gokce Belge Bilgin, Yalda Nikanpour, Geoffrey B. Johnson, Benjamin R. Kipp, David M. Zahrieh, Katherine B. Geiersbach, Matthew S. Block, Svetomir N. Markovic   +8 more
wiley   +1 more source

Circulating tumor DNA in patients with cancer: insights from clinical laboratory

Advances in Laboratory Medicine
Blood-based circulating tumor DNA (ctDNA) analysis has emerged as a highly relevant non-invasive method for molecular profiling of solid tumors, offering valuable information about the genetic landscape of cancer.
Illana Francisco J., Fernández-Galán Esther, Muñoz-Bravo José Luis, Valiña Amado Laura, García Martín Carme, González-Fernández Carolina, Miró-Cañís Sílvia, Trapé Jaume, Martínez-Peinado Antonio, Filella Xavier, González Alvaro, Sánchez Antonio Barco, Díaz-Lagares Angel,   +13 more
doaj   +1 more source

EGFR inhibition in NSCLC: New findings\u2026. and opened questions? [PDF]

, 2017
The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum ...
Bazan, V., Castiglia, M., Listi', A., Passiglia, F., Perez, A., Rizzo, S., Russo, A.   +6 more
core   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source